The 21 references in paper N. Musina Z., V. Fedyaeva K., V. Omel’yanovskii V., G. Khachatryan R., K. Gerasimova V., V. Lemeshko A., K. Konchits P., Н. Мусина З., В. Федяева К., В. Омельяновский В., Г. Хачатрян Р., К. Герасимова В., В. Лемешко А., К. Кончиц П. (2017) “Oбзор существующих зарубежных подходов к определению и оценке инновационности лекарственных препаратов // Review of the current approaches to the assessment of the drug innovative potential worldwide” / spz:neicon:pharmacoeconomics:y:2017:i:3:p:66-74

1
Dremova N. B. Novaya apteka (in Russian). 2006; 8: 65-79.
(check this in PDF content)
2
Medynskii V. G. Innovative management: a textbook [Innovatsionnyi menedzhment: uchebnik (in Russian)]. Moscow. 2005; 293 s.
(check this in PDF content)
3
U.S. Food and Drug Administration: Drug Development and Review Definitions. URL: http://www.fda.gov/drugs/developmentapprovalprocess/ howdrugsaredevelopedandapproved/approvalapplications/. Accessed: 25.07.2017.
(check this in PDF content)
4
AIFA, Model for ranking the therapeutic innovation for a new drug. URL: https://www.agenziafarmaco.it/allegati/intergral_ document.pdf. Accessed: 28.07.2017.
(check this in PDF content)
5
The Use of Health Technology Assessments (HTA) to evaluate Medicines. Principles and guidance for implementation in different healthcare environments. EFPIA HTA Toolkit – Final. 04.02.2008.
(check this in PDF content)
6
Khachatryan G. R., A. V. Luneva A. V. Innovatsii v meditsine i opredelenie ikh tsennosti v zarubezhnykh stranakh: obzor literatury. Meditsinskie tekhnologii: otsenka i vybor. 2013; 4 (14): 23-29.
(check this in PDF content)
7
Senatore P., Chalmers M., Cyrus A. The New AIFA Algorithm For Assessing ‘Innovativeness’ Of New Products In Italy: So What? 18 August 2017. URL: http://cbpartners.com/blog/new-aifa-algorithm-assessinginnovativeness-new-products-italy.html. Accessed: 02.07.2017 .
(check this in PDF content)
8
Schlenkrich S. The Act on the Reform of the Market for Medicinal Products (AMNOG): A Question of Power?! Anchor Academic Publishing (aap_verlag), 2015.
(check this in PDF content)
9
Pricing & Reimbursement of drugs and HTA policies in France. National Authority for health (Haute Autorité de Santé), France march 2014. URL: https://www.has-sante.fr/portail/upload/docs/application/ pdf/2014-03/pricing_reimbursement_of_drugs_and_hta_policies_in_ france.pdf. Accessed: 01.07.2017.
(check this in PDF content)
10
Haute autorite de sante (HAS). URL: www.has-sante.fr. Accessed: 29.07.2017.
(check this in PDF content)
11
Pricing & Reimbursement of drugs and HTA policies in France. National Authority for health (Haute Autorité de Santé), France march 2014. URL: https://www.has-sante.fr/portail/upload/docs/application/ pdf/2014-03/pricing_reimbursement_of_drugs_and_hta_policies_in_ france.pdf. Accessed: 01.07.2017.
(check this in PDF content)
12
Paris V., Belloni A. Value in pharmaceutical pricing. 2013. URL: https://www.oecd.org/canada/Value-in-Pharmaceutical-PricingCanada.pdf Accessed: 29.07.2017.
(check this in PDF content)
13
World Health Organization et al. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. WHO Regional Office for Europe. 2015.
(check this in PDF content)
14
Omel’yanovskii V.V., Sura M. V., Sveshnikova N. D. Meditsinskie tekhnologii: otsenka i vybor (in Russian). 2011; 1 (3): 40
(check this in PDF content)
15
Paris V., Belloni A. Value in pharmaceutical pricing – country profile: Canada. 2014. URL: https://www.oecd.org/canada/Value-inPharmaceutical-Pricing-Canada.pdf . Accessed: 05.07.2017.
(check this in PDF content)
16
Market Access Challenges in 2017: Impacts of Japan’s Drug Pricing Policy Reforms. URL: https://decisionresourcesgroup.com/ drg-blog/market-access-challenges-2017-impacts-japans-drugpricing-policy-reforms/. Accessed: 05.07.2017
(check this in PDF content)
17
Hirashima S., T. Shigihara. JPMA Challenges Updates. JPMA meeting 2016.
(check this in PDF content)
18
Drug Pricing System in Japan. Ministry of Health, Labour, and welfare Insurance Bureau, 2016. URL: http://www.jpma.or.jp/english/ parj/pdf/17_supplement.pdf Accessed: 05.07.2017.
(check this in PDF content)
19
Hideyuki K., Toshiyuki H., Konomi I., Hisashi K., Noriatsu K. The Current Status of Sakigake Designation in Japan, PRIME in the European Union, and Breakthrough Therapy Designation in the United States. Therapeutic Innovation & Regulatory Science. 2016; 51 (1): 51-54.
(check this in PDF content)
20
Matsunaga Y. National Health Insurance (NHI) pricing formula in Japan. Improvement in methodology of pricing for new drugs and orphan drugs, 2014. URL: https://www.pmda.go.jp/files/000152228. pdf. Accessed: 06.07.2017.
(check this in PDF content)
21
Postanovlenie Pravitel’stva RF ot 15.04.2014 N 30 (red. ot 31.03.2017) «Ob utverzhdenii gosudarstvennoi programmy Rossiiskoi Federatsii «Razvitie farmatsevticheskoi i meditsinskoi promyshlennosti» na 2013-2020 gody». URL: http://www.pravo.gov.ru. Accessed: 29.07.2017. Сведения об авторах:
(check this in PDF content)